# Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder

> **NCT02849548** · PHASE4 · COMPLETED · sponsor: **Howard University** · enrollment: 27 (actual)

## Conditions studied

- Posttraumatic Stress Disorder

## Interventions

- **DRUG:** suvorexant
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT02849548
- **Lead sponsor:** Howard University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-03
- **Primary completion:** 2021-05-17
- **Final completion:** 2021-05-19
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02849548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02849548, "Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02849548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*